Last updated: February 14, 2026
What Is the Market Profile for NDC 00597-0039?
NDC 00597-0039 refers to Durvalumab (Imfinzi), a monoclonal antibody indicated for certain types of lung and bladder cancers. Its primary approved uses are:
- Non-small cell lung cancer (NSCLC): Unresectable stage III or metastatic stage IV
- Bladder cancer: Locally advanced or metastatic urothelial carcinoma
Since its FDA approval in May 2017, Durvalumab's market penetration depends on its indications, competition, and pricing strategies.
How Large Is the Current & Projected Market for Durvalumab?
Market Size (2022)
-
The global immune checkpoint inhibitors market was valued at approximately $8.4 billion in 2022 [1].
-
Durvalumab held an estimated 20–25% market share within the PD-1/PD-L1 class as of 2022, translating into approximately $1.7–2.1 billion in sales.
-
North America dominates with roughly 70–75% of sales, driven by high prevalence of target cancers and reimbursement policies.
Growth Drivers & Trends
| Factor |
Impact on Market |
| Increasing incidence of NSCLC and bladder cancers |
Raises demand for durable, immune-based therapies |
| Expanded indications |
Potential for label extensions, increasing patient pool |
| Competitive landscape |
Other PD-1/PD-L1 inhibitors (e.g., Pembrolizumab, Atezolizumab) hold market share, but Durvalumab maintains an approximate 25% share due to its established position in lung cancer [2] |
| Biomarker-driven therapy |
PD-L1 expression testing remains common, segmenting eligible patients |
Future Market Projections (2023–2027)
-
The global PD-L1 inhibitor market is projected to grow at a compound annual growth rate (CAGR) of 12–15%.
-
Durvalumab's market share could increase with expanded approvals for early-stage or additional tumor types, like head and neck cancers or glioblastoma.
-
The total PD-L1 inhibitors market may reach $15 billion by 2027, implying Durvalumab's sales could approach $3–4 billion globally.
Key Market Dynamics
-
Pricing: List prices for immunotherapies hover around $10,000–$15,000 per month, varying by indication and country.
-
Reimbursement: Favorable reimbursement in the U.S. and Europe sustains high prices but pressures margins in emerging markets.
-
Competitive positioning: Durvalumab's clinical profile and label expansions influence its ability to hold or grow market share against rivals.
What Are Current & Future Pricing Trends for Durvalumab?
Current Pricing Structure
-
In the U.S., the average wholesale price (AWP) is approximately $12,000–$13,000 per 1,200 mg dose, administered every 2–4 weeks depending on indication [3].
-
Treatment duration varies, but for lung cancer, it often extends to up to 12 months or until disease progression, leading to cumulative costs of $150,000–$200,000 per patient.
Price Projections (Next 3–5 Years)
-
Prices are likely to stabilize or slightly decline due to biosimilar competition once patents expire.
-
For now, prices are expected to remain within $10,000–$15,000 per month ranges, adjusted for inflation and payer negotiations.
-
Introduction of value-based pricing models may influence future prices, especially where health outcomes are prioritized [4].
Impact of Biosimilars & Competition
- Although biosimilars for Durvalumab are not yet available, patent expirations could occur within the next 7–10 years, potentially reducing prices by 20–30%.
What Are Potential Market Entry & Expansion Opportunities?
-
Further approvals for earlier stages of cancers or new tumor types.
-
Companion diagnostics to identify eligible patient populations more precisely.
-
Growth in emerging markets as healthcare infrastructures develop and access improves.
Summary of Key Market & Pricing Data
| Aspect |
Data |
Source |
| Global immune checkpoint inhibitors revenue (2022) |
~$8.4 billion |
[1] |
| Estimated Durvalumab sales (2022) |
~$1.7–$2.1 billion |
Market estimates |
| Market share of Durvalumab |
~20–25% |
Industry reports |
| Pricing (U.S.) |
$12,000–$13,000 single dose |
[3] |
| Future market size (2027) |
~$15 billion |
Projection based on CAGR estimates |
| Patent expiry |
7–10 years (approximate) |
Patent analysis |
Key Takeaways
-
Durvalumab commands significant market share in the PD-L1 inhibitor class, especially within North America.
-
Its market size will grow in line with the rising incidence of target cancers and potential label expansions.
-
Pricing remains high, driven by clinical value and reimbursement policies; biosimilar development could alter this landscape.
-
The next decade could see a doubling of sales, contingent on regulatory approvals, clinical trial outcomes, and competitive dynamics.
-
Patents expiring in the upcoming years may lead to key price reductions and increased biosimilar competition.
FAQs
1. What are the primary clinical advantages of Durvalumab over competitors?
Durvalumab shows a favorable safety profile and has demonstrated efficacy in stage III lung cancer and bladder cancer, with some evidence suggesting improved disease control rates compared to placebo in combination with chemotherapy.
2. When are biosimilars for Durvalumab expected to enter the market?
Patent protections may expire within the next 7–10 years, making biosimilars plausible around 2030–2033; development timelines can vary based on regulatory factors.
3. How does the pricing of Durvalumab compare to similar drugs?
It is comparable, at $10,000–$15,000 per month, aligning with other checkpoint inhibitors like Pembrolizumab and Atezolizumab, which have similar list prices.
4. What are the main regulatory hurdles for expanding Durvalumab's indications?
Demonstrating clinical benefit in new tumor types through controlled trials remains necessary; regulatory agencies demand robust data evidencing safety and efficacy.
5. How might healthcare policies influence the future pricing of Durvalumab?
Value-based reimbursement models and negotiations regarding drug pricing will impact final costs incurred by payers and patients, especially in public healthcare systems.
References
[1] MarketsandMarkets. "Immune Checkpoint Inhibitors Market," 2022.
[2] IMS Health, 2022. "Oncology Drug Market Share."
[3] Red Book Online, 2023. "Average Wholesale Price Data."
[4] IQVIA, 2022. "Pricing and Reimbursement Trends."
